Key facts
- It has raised $150K; the latest was Angel (individual) ($150K) in Nov 2025.
- Paretor has filed 1 Form D with the SEC, most recently Dec 2025 ($105K sold to 1 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Paretor
- ·The full record, as it builds
Funding rounds
No funding rounds for Paretor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Paretor
Developer of standardized RNA transfection reagents designed to simplify and scale RNA delivery for clinical applications. The company offers nanoparticle reagents formulated for controlled, scalable RNA delivery from laboratory studies to clinical development, enabling resolution of technical limitations in RNA transfer and a smoother transition to GMP manufacturing for RNA-based products.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2024
- Website
- paretorbio.com/
- Ownership
- Privately Held (backing)
Paretor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paretor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paretor in its N-PORT filings yet. We sweep new filings monthly.